The FDA has cleared InDevR's FluChip-8G Influenza A+B Assay, enabling the detection of non-seasonal and seasonal influenza viruses in a single multiplexed assay. This technology can identify emerging strains like H7N9 and H5N1 with high accuracy.
InDevR to showcase VaxArray technology at the BIO International Convention, leveraging NIH SBIR/STTR funding. The company has a proven track record of translating scientific ideas into commercial products.
InDevR launches first-in-class reagent kit for rapid quantification of N9 in 'pandemic' influenza vaccines. The VaxArray assays are expected to reduce time and cost associated with vaccine production, facilitating improvement of seasonal and pandemic influenza vaccines.
InDevR's new VaxArray kit offers a standardized method to measure neuraminidase in influenza vaccines, improving accuracy and precision. This assay is expected to aid in the development of more broadly protective flu vaccines by enabling manufacturers to meet current regulatory requirements.
Researchers are collaborating with AFRIMS to test FluChip-8G Insight system for rapid characterization of influenza virus subtype from human and animal-origin samples. The system has been installed at AFRIMS sites in Bangkok, Kathmandu, and Manila, and will conduct side-by-side performance comparison with real-time RT-PCR assays.
The FluChip-8G test promises to reduce influenza A and B characterization times from two weeks to eight hours. The study uses the test alongside standardized WHO/CDC rRT-PCR tests, employing specimens collected from various locations including Vietnam, Malaysia, and the US.
The project leverages the multiplexed VaxArray platform to deliver high-quality MR vaccines faster and at lower production costs. Measles and rubella vaccines can prevent these highly contagious diseases, which have had a significant impact globally.
InDevR's VaxArray Influenza Pandemic HA potency assay enables rapid assessment of vaccine potency, reducing bottlenecks in vaccine production and administration. The assay demonstrates high sensitivity, accuracy, precision, and detection of a large panel of influenza viruses with pandemic potential.
The VaxArray NA reagent kit provides a standardized method for assessing neuraminidase in influenza vaccines, enabling manufacturers to meet current regulatory requirements and prepare for future trends. This breakthrough tool is expected to serve as an important new asset in the push for a more broadly protective or 'universal' flu va...
A new study shows a predictive link between VaxArray-measured potency and vaccine-induced immunogenicity in mice. The study found strong correlations between VaxArray assays and serum levels of antibodies targeting influenza hemagglutinin and neuraminidase.
The new test kit, developed with licensed monoclonal antibodies from the US FDA, offers a rapid and sensitive potency assay for dose-sparing and adjuvanted flu vaccines. This enables a faster vaccine response in severe outbreaks or pandemics, addressing the need for speed in combating deadly avian H7N9 viruses.
The new FluChip-8G technology uses microarray analysis and artificial intelligence to identify flu viruses, providing rapid and detailed information for enhanced influenza surveillance. This will enable early warning systems in remote locations to detect potential pandemic threats.